Blood disorders: future trends in iron chelation.
The treatment of iron overload in thalassaemic patients has for some time involved long periods of subcutaneous drug therapy. The inconvenience of sporting a portable syringe driver for up to ten hours at a time has led to reduced patient compliance rates, particularly among adolescent and teenage groups. Dorothy Jordan and George Kontoghiorghes describe a recent breakthrough which could result in many patients being able to resort to oral iron chelation therapy.
Jordan
D
D
Kontoghiorghes
G
G
D000293:Adolescent; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000506:poisoning*; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D011041:Poisoning / Q000188:drug therapy / Q000503:physiopathology; D011728:Pyridones / Q000627:therapeutic use; D013789:Thalassemia / Q000628:therapy*; D065227:Transfusion Reaction
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine